% 0期刊文章%一个凯瑟琳·阿尔伯斯艾丽卡伯德% %撒母耳高盛%一个Raymond Lo Jeffrey Klingman % %一个紫水晶Leimpeter康尼马拉% %一个凯萨琳Comyns罗宾Fross % % Zhuqin Gu %一个玛雅Katz %劳里Ozelius %一个瑞秋Saunders-Pullman苏珊Bressman % %辛西娅·考米拉% Lorene Nelson %一个斯蒂芬·范Eeden %卡罗琳·坦纳% T睑痉挛的多民族人口(P3.348) % D J神经病学2016% % P P3.348 X % V % 86% N 16补充目的:确定无力睑痉挛的发生率和前期诊断特征在一个大型的、多民族的综合健康维护组织。首页背景:睑痉挛发生率有有限的数据和之前的报告都是基于少数病例。设计/方法:事件睑痉挛病例中使用电子病历回顾> 300万名Kaiser Permanente加州北部(KPNC) 2003 - 2007。最后的诊断是由两个运动障碍专家的共识。发病率是标准化使用2000年美国人口普查。控制匹配对年龄、性别和会员持续时间(1例:10控制)。使用逻辑回归调整优势比测定年龄,性别和会员持续时间。美国2000年人口普查结果:睑痉挛发生率标准化人口1.45/100000组(95 [percnt] CI, 0.53 - 2.37;女人:2.05,男人:0.83)基于246例/ 1540万人年的风险。通过第八十年发病率随着年龄的增加,在白种人(1.58)最高,其次为亚洲人(1.32),非裔美国人(1.08)与(0.95)的原住民。 Ocular diagnoses more common in patients with blepharospasm compared to controls before index date included were eye allergy (OR 2.82, 95[percnt] CI, 1.69 to 4.7), dry eyes (OR 9.19, 95[percnt] CI, 6.22 to 13.58), glaucoma (OR 2.76, 95[percnt] CI, 1.28 to 5.95), eye injury (OR 2.38, 95[percnt] CI, 1.44 to 3.94) and eye infection (OR 3.76, 95[percnt] CI, 2.58 to 5.47). Conclusions: Blepharospasm incidence is higher in women, in those of increasing age and of Caucasian race. Diagnoses preceding blepharospasm may reflect comorbid conditions, diagnostic errors or etiologic factors. Support: NIH-1R01-NS046340, AHRQ-R01-HS018413, Dystonia Medical Research Foundation, KPNC, James and Sharron ClarkDisclosure: Dr. Byrd has nothing to disclose. Dr. Albers has nothing to disclose. Dr. Goldman has nothing to disclose. Dr. Klingman has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Marras has nothing to disclose. Dr. Leimpeter has nothing to disclose. Dr. Fross has nothing to disclose. Dr. Comyns has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Katz has nothing to disclose. Dr. Ozelius has nothing to disclose. Dr. Bressman has nothing to disclose. Dr. Saunders-Pullman has nothing to disclose. Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan, Medtronic, Teva, US World Meds, Impax, Acadia, Acorda, Revance, Neurocrine, and Ultragenx Pharmaceuticals as a consultant. Dr. Comella has received research support Dr. Nelson has received compensation from Neuropace Inc. for service on a DSMB, and from Acumen, LLC for epidemiology consulting. Dr. Van Den Eeden has nothing to disclose. Dr. Tanner has received personal compensation for activities with Neurocrine and Ultragenyx Pharmaceuticals as a consultant.Monday, April 18 2016, 8:30 am-7:00 pm %U